Compare · MDAI vs WST
MDAI vs WST
Side-by-side comparison of Spectral AI Inc. (MDAI) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDAI and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $23.77B, about 436.7x MDAI ($54.4M).
- Over the past year, MDAI is down 18.8% and WST is up 51.0% - WST leads by 69.8 points.
- MDAI has been more active in the news (5 items in the past 4 weeks vs 4 for WST).
- WST has more recent analyst coverage (17 ratings vs 1 for MDAI).
- Company
- Spectral AI Inc.
- West Pharmaceutical Services Inc.
- Price
- $1.73-1.71%
- $336.44+2.03%
- Market cap
- $54.4M
- $23.77B
- 1M return
- -34.66%
- +6.44%
- 1Y return
- -18.82%
- +51.00%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 5
- 4
- Recent ratings
- 1
- 17
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest MDAI
- Spectral AI Joins the American Board of Wound Management Foundation in Celebrating Wound Healing Awareness Month
- Spectral AI to Participate in 2026 British Burn Association Annual Conference
- Spectral AI Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits
- Director Dimaio John Michael was granted 17,500 shares, increasing direct ownership by 0.66% to 2,687,847 units (SEC Form 4)
- Spectral AI Announces Voting Results of Annual Meeting of Stockholders
- Director Dimaio John Michael was granted 32,233 shares, increasing direct ownership by 1% to 2,670,347 units (SEC Form 4)
- Spectral AI Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Spectral AI Receives FDA De Novo Clearance for DeepView® System for Burn Indication
- Director Sadagopan Deepak was granted 25,000 shares (SEC Form 4)
- Director Cotton Richard John was granted 14,700 shares, increasing direct ownership by 15% to 111,477 units (SEC Form 4)
Latest WST
- West Pharm upgraded by Barclays with a new price target
- Wolfe Research resumed coverage on West Pharm with a new price target
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- West Appoints Michel Lagarde to be President and Chief Executive Officer
- Amendment: West Pharmaceutical Services Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SVP, Proprietary Segment Campbell Shane Alden covered exercise/tax liability with 219 shares and converted options into 770 shares, increasing direct ownership by 881% to 613 units (SEC Form 4)
- SEC Form SD filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Director Pucci Paolo was granted 791 shares, increasing direct ownership by 7% to 11,854 units (SEC Form 4)
- Director Michels Douglas A was granted 791 shares, increasing direct ownership by 2% to 46,496 units (SEC Form 4)